Personalised Cancer Vaccine Cuts Risk of Melanoma Recurrence in Trial

A personalised cancer vaccine combined with immunotherapy reduced the risk of death or melanoma returning by 42 per cent in a clinical trial.

The finding points to the potential of personalised vaccination as part of treatment for melanoma, a form of skin cancer.

The reported reduction applies to the combined risk of death or recurrence. It does not mean the vaccine prevented 42 per cent of deaths or recurrences when each outcome is considered separately.

The result was reported for the vaccine used alongside immunotherapy, rather than as a standalone treatment. The summary did not specify the trial’s size, follow-up period or comparison treatment.

Further details would be needed to assess how broadly the findings could apply and whether the approach could become available beyond clinical trials.